PDF(Pubmed)
Abstract：
Atrial fibrillation (AF) is a type of cardiac arrhythmia causing shortness of breath, lightheadedness, and palpitations. It may go unrecognized and asymptomatic among many patients. AF is not a potentially fatal arrhythmia; its hemodynamic, structural, and hemocoagulative effects have a significant impact on the standard of life, which can lead to various complications such as stroke. A stroke caused by AF leads to additional burdens on both patients and the global economy. Patients with AF can prevent strokes with oral anticoagulants; however, ensuring diligent adherence to medication is crucial for maximizing treatment efficacy. Since they have a lighter treatment load than warfarin, non-vitamin K antagonist oral anticoagulants (NOACs) are also recommended with better hope for medication adherence. Various anticoagulants such as warfarin and ximelagatran, among many more, are prescribed to patients who have the potential to reduce the incidence of stroke as well as alleviate their likelihood of developing other thromboembolic events that can decrease their quality of life. Economic and psychological burdens associated with diminished functionality can be prevented by anticoagulant therapy among AF patients, therefore reducing their economic and social burden. This is due to the negative association between stroke among AF patients and anticoagulation consumption.
摘要：
心房颤动（AF）是一种引起呼吸急促的心律失常，头昏眼花,还有心悸.在许多患者中，它可能无法识别和无症状。AF不是潜在的致命心律失常;它的血液动力学,结构,凝血效应对生活水平有重大影响，这可能导致各种并发症，如中风。由AF引起的中风导致患者和全球经济的额外负担。房颤患者可以通过口服抗凝剂预防中风；然而，确保坚持用药对于最大限度地提高治疗效果至关重要。因为它们的治疗负荷比华法林轻，非维生素K拮抗剂口服抗凝药(NOACs)也被推荐,希望更好地坚持用药.各种抗凝剂，如华法林和ximelagatran，在更多的，为有可能降低卒中发生率并减轻发生其他可能降低生活质量的血栓栓塞事件的患者开处方。房颤患者的抗凝治疗可以预防与功能下降相关的经济和心理负担。从而减轻他们的经济和社会负担。这是由于房颤患者的卒中与抗凝消耗之间存在负相关。
